GlassScriptPhysician profile
Rabia A Khan
NPI 1790857407
$1,381.16
in general payments reported to CMS, 2019-2025
11 companies · $418 in 2025
The $418 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $74.65 · 2023: $113 · 2024: $776 · 2025: $418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,307.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,306.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $603.37 | 2023-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Argenx US, INC. | $249.36 | 2024-2025 | Vyvgart |
| Sk Life Science, INC. | $221.24 | 2021-2024 | Xcopri |
| Jazz Pharmaceuticals INC. | $107.36 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $42.01 | 2025 | Lifevest |
| Abbvie INC. | $37.00 | 2024 | |
| Celgene Corporation | $36.52 | 2024-2025 | Zeposia |
| Genentech USA, INC. | $31.53 | 2024 | Ocrevus, Enspryng |
| Lilly USA, LLC | $23.79 | 2024 | Amyvid |
| Sumitomo Pharma America, INC. | $15.00 | 2024 | Aptiom |
| Scilex Pharmaceuticals INC. | $13.98 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rabia Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.